Lumex

Lumex is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.

Lumex is an antibiotic in a class of drugs called fluoroquinolones. It fights bacteria in the body.

Lumex is used to treat various bacterial infections, such as bronchitis and urinary tract infections.

Lumex is an antibiotic in a class of drugs called fluoroquinolones. It fights bacteria in the body.

Lumex is used to treat various bacterial infections, such as bronchitis and urinary tract infections.

Lumex may also be used for purposes other than those listed in this medication guide.

Applies to the following strengths: 400 mg

Usual Adult Dose for:

• Bronchitis
• Cystitis
• Prostatitis
• Salmonella Enteric Fever
• Salmonella Gastroenteritis
• Shigellosis
• Transurethral Prostatectomy
• Urinary Tract Infection

Additional dosage information:

• Renal Dose Adjustments
• Liver Dose Adjustments
• Dose Adjustments
• Precautions
• Dialysis
• Other Comments

Usual Adult Dose for Bronchitis

400 mg orally once a day for 10 days

Usual Adult Dose for Cystitis

400 mg orally once a day for 3 days

Duration: 3 days if caused by E coli in females; 10 days if caused by K pneumoniae, P mirabilis, or S saprophyticus

Usual Adult Dose for Prostatitis

400 mg orally once a day for 14 to 30 days

Usual Adult Dose for Salmonella Enteric Fever

400 mg orally once a day for 7 to 14 days

Usual Adult Dose for Salmonella Gastroenteritis

400 mg orally once a day for 3 days

Usual Adult Dose for Shigellosis

400 mg orally once a day for 3 to 5 days

Usual Adult Dose for Transurethral Prostatectomy

400 mg orally 2 to 6 hours prior to procedure

Usual Adult Dose for Urinary Tract Infection

Complicated: 400 mg orally once a day for 14 days

Renal Dose Adjustments

CrCl 10 to 40 mL/min: Loading dose of 400 mg followed by 200 mg orally once a day

Liver Dose Adjustments

No adjustment recommended

Dose Adjustments

It is suggested that serial determinations of Lumex levels be performed to determine any necessary alteration in the appropriate next dosing interval for renal dysfunction patients.

Precautions

Recommended doses should not be exceeded due to increased risk of QT interval prolongation. Discontinue use and initiate appropriate therapy if signs of QT interval prolongation, seizures, neuropathy, or hypersensitivity occur.

Patients should be advised to avoid direct or indirect exposure to sunlight and artificial UV light, and to take Lumex at least 12 hours before exposure to sunlight (in the evening) as this may decrease the risk of phototoxic reactions. The drug should be discontinued if signs of phototoxicity occur (e.g., sunburn, redness, burning, itching, rash, blistering).

Patients should be advised to discontinue the drug, rest, and avoid exercise if they experience pain, inflammation or rupture of a tendon.

Clostridium difficile associated diarrhea (CDAD) has been reported with almost all antibiotics and may potentially be life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea following quinolone therapy. Mild cases generally improve with discontinuation of the drug, while severe cases may require supportive therapy and treatment with an antimicrobial agent effective against C difficile. Hypertoxin producing strains of C difficile cause increased morbidity and mortality; these infections can be resistant to antimicrobial treatment and may necessitate colectomy.

The patient should be well hydrated or instructed to drink plenty of water to avoid formation of highly concentrated urine.

Renal, hepatic, and hematopoietic function should be monitored periodically during therapy.

Dosage adjustments are recommended for renally impaired patients. Caution and monitoring is recommended for elderly patients, who may be at a greater risk of adverse reactions due to declining renal function.

Lumex may cause dizziness or lightheadedness. Patients should be advised to avoid driving or engaging in other tasks requiring alertness and coordination until they know how the drug affects them.

Due to cartilage erosion and arthropathy reported in studies with juvenile animals, the safety and effectiveness of Lumex in pediatric patients and adolescents less than 18 years have not been established.

Dialysis

Conventional hemodialysis removes only a negligible amount of Lumex (3%). Hemodialysis patients should receive an initial loading dose of 400 mg followed by daily maintenance doses of 200 mg once a day.

Other Comments

Lumex may be taken without regard to meals. Patients should be advised to drink plenty of fluids. Doses should be administered at least 4 hours before or 8 hours after iron-, zinc-, aluminum-, or magnesium-containing compounds (e.g., antacids, sucralfate, mineral supplements, buffered didanosine).

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

More about Lumex

• Lumex Side Effects
• During Pregnancy or Breastfeeding
• Drug Interactions
• Drug class: quinolones

Professional resources

Related treatment guides

• Bladder Infection
• Bronchitis
• Prostatitis
• Salmonella Enteric Fever
• ... +4 more

See also:
What is the most important information I should know about Lumex?

Before taking Lumex, tell your doctor if you have

kidney disease; or

seizures or epilepsy.

You may not be able to take Lumex, or you may require a dosage adjustment or special monitoring during treatment.

Use Lumex as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Lumex may be taken with or without food.
• Take Lumex with a full glass (8 oz/240 mL) of water. Also, drink several additional glasses of water each day.
• Lumex should be taken 2 hours before or 4 hours after the following medicines: antacids containing aluminum, calcium, or magnesium; didanosine; iron salts (eg, ferrous sulfate); sucralfate; or zinc salts (eg, zinc sulfate).
• Lumex works best if it is taken at the same time each day.
• To clear up your infection completely, continue using Lumex for the full course of treatment even if you feel better in a few days.
• If you miss a dose of Lumex, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Lumex.

Lumex is used to treat infections caused by bacteria, especially lower respiratory tract infections and urinary tract infections.

See also:
What other drugs will affect Lumex?

Theophylline: In three pharmacokinetic studies including 46 normal, healthy subjects, theophylline clearance and concentration were not significantly altered by the addition of Lumex. In clinical studies where patients were on chronic theophylline therapy, Lumex had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance. Though individual theophylline levels fluctuated, there were no clinically significant symptoms of drug inter-action.

Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx® (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with Lumex and interfere with its bioavailability. Sucralfate administered 2 hours before Lumex resulted in a slower absorption (mean C _max decreased by 30% and mean T _max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%). Magnesium- and aluminum-containing antacids, administered concomitantly with Lumex, significantly decreased the bioavailability (48%) of Lumex. Separating the doses of antacid and Lumex minimizes this decrease in bioavailability; therefore, administration of these agents should precede Lumex dosing by 4 hours or follow Lumex dosing by at least 2 hours.

Caffeine: Two hundred mg of caffeine (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of Lumex after being dosed at 400 mg qd. This did not result in any statistically or clinically relevant changes in the pharmacokinetic parameters of either caffeine or its major metabolite, paraxanthine. No data are available on potential interactions in individuals who consume greater than 200 mg of caffeine per day or in those, such as the geriatric population, who are generally believed to be more susceptible to the development of drug-induced CNS-related adverse effects. Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine.

Cimetidine: Cimetidine has been demonstrated to interfere with the elimination of other quinolones. This interference has resulted in significant increases in half-life and AUC. The interaction between Lumex and cimetidine has not been studied.

Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class. Interaction between Lumex and cyclosporine has not been studied.

Omeprazole: No clinically significant changes in Lumex pharmacokinetics (AUC, C _max, or T _max ) were observed when a single dose of Lumex 400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers. Changes in omeprazole pharmacokinetics were not studied.

Phenytoin: No significant differences were observed in mean phenytoin AUC, C _max, C _min or T _max (although C _max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with Lumex (400 mg qd) for five days in 15 healthy males. Lumex is unlikely to have a significant effect on phenytoin metabolism.

Probenecid: Probenecid slows the renal elimination of lome-floxacin. An increase of 63% in the mean AUC and increases of 50% and 4%, respectively, in the mean T _max and mean C _max were noted in 1 study of 6 individuals.

Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or Lumex pharmacokinetics, during concurrent administration of Lumex and terfenadine at steady-state in 28 healthy males.

Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives. When these products are administered concomitantly, prothrombin or other suitable coagulation tests should be monitored closely. However, no clinically or statistically significant differences in prothrombin time ratio or warfarin enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both warfarin and Lumex under steady-state conditions.

See also:
What are the possible side effects of Lumex?

Nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, headache, dizziness,

sleep disorders, rash (rarely Stevens-Johnson syndrome and toxic epidermal necrolysis), pruritus, flatulence, dysphagia, tremor, hyperglycaemia,

altered prothrombin concentration, casualties, petechiae,

haemorrhagic bullae, tinnitus, tenosynovitis, tachycardia, oedema, syncope,

hot flushes and sweating. Less frequent adverse reactions include

anorexia, increase in blood urea and creatinine, drowsiness, restlessness,

asthenia, depression, confusion, hallucinations, convulsions, paraesthesia,

photosensitivity, hypersensitivity reactions including fever, urticaria,

angioedema, arthralgia, myalgia, and anaphylaxis; blood disorders

(including eosinophilia, leucopenia, thrombocytopenia); disturbances in

vision, hearing, taste and smell. Also isolated reports of tendon inflammation

and damage especially in the elderly and in those taking corticosteroids.

Other adverse reactions that have been reported include haemolytic

anaemia, renal failure, interstitial nephritis and hepatic dysfunction

including hepatitis and cholestatic jaundice.

USE DURING PREGNANCY AND LACTATION:

Ciprofloxacin must not be prescribed to pregnant women or to nursing mothers,

since there is no experience with the drug safety in these patients

groups and since animal studies indicate that damage to articular cartilage in

the immature organism can not be fully excluded. Animal studies have not

yielded any evidence of teratogenic effects (malformations).